Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827625 | 0.80 | HSD17B3 (0.50) | ALDH1A1KDM4EHSD17B3 | |
| SCHEMBL1829208 | 0.79 | RXFP1 (0.50) | RXFP1ALDH1A1KDM4EGAAGPR84 | |
| SCHEMBL6763737 | 0.67 | MAPT (0.50) | RXFP1ALDH1A1KDM4EGAAHSD17B3 | |
| SCHEMBL12658564 | 0.66 | MEN1 (0.41) | KDM4EGAAHSD17B3SMYD3LMNA | |
| SCHEMBL11347318 | 0.66 | GPR84 (0.44) | RXFP1ALDH1A1KDM4EGAAGPR84 | |
| SCHEMBL11343726 | 0.66 | GPR84 (0.44) | RXFP1ALDH1A1KDM4EGAAGPR84 | |
| SCHEMBL11343991 | 0.66 | GPR84 (0.44) | RXFP1ALDH1A1KDM4EGAAGPR84 | |
| SCHEMBL11335616 | 0.66 | SMN1; SMN2 (0.43) | RXFP1ALDH1A1KDM4EGAAGPR84 | |
| SCHEMBL11354053 | 0.65 | GPR84 (0.43) | RXFP1ALDH1A1KDM4EGAAGPR84 | |
| SCHEMBL4851937 | 0.64 | KDM4E (0.41) | ALDH1A1KDM4EGAASMYD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MIF, IL1B, IL1A | RXFP1 589/4885ALDH1A1 329/4885KDM4E 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.